Literature DB >> 19304865

Are depot antipsychotics more coercive than tablets? The patient's perspective.

M X Patel1, N de Zoysa, M Bernadt, J Bindman, A S David.   

Abstract

Some clinicians consider depot antipsychotics to be stigmatising, coercive and unacceptable to patients. This cross-sectional study investigated patients' perspectives of coercion for depot and oral antipsychotics. In all, 72 participants with chronic mental illness on voluntary maintenance antipsychotic medication were interviewed for their views on oral and depot medication and experiences of coercion. The MacArthur Admission Experience (short form) was adapted to explore coercion regarding medication. Mean total coercion levels were higher for those on depot (depot: mean 4.39; oral: 2.80, P = 0.027), as were perceived coercion (2.52 vs 1.73, P = 0.041) and negative pressures subscales (1.17 vs 0.33, P = 0.009). No significant differences were found for the 'voice' subscale and affective reactions. Specifically, more participants on depot felt that people try to force them to take medication (30% vs 2%, P< 0.001). Depots were perceived as more coercive than oral antipsychotics. Greater perceived coercion may explain why some consider depots to be a more stigmatising form of treatment. Although forced medication is sometimes required, the experience of coercion should be minimised by giving patients a fair say in treatment decisions, regardless of formulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19304865     DOI: 10.1177/0269881109103133

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  15 in total

1.  A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.

Authors:  Amlan K Das; Abid Malik; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Managing non-adherence and the 3 Cs: collaboration, cash and coercion.

Authors:  Anthony S David
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

3.  The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria.

Authors:  Bawo O James; Joyce O Omoaregba; Kingsley M Okonoda; Edebi U Otefe; Maxine X Patel
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

4.  Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Authors:  Matthias Kirschner; Anastasia Theodoridou; Paolo Fusar-Poli; Stefan Kaiser; Matthias Jäger
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

5.  Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.

Authors:  Shiyun Kim; Hugo Solari; Peter J Weiden; Jeffrey R Bishop
Journal:  Patient Prefer Adherence       Date:  2012-07-13       Impact factor: 2.711

6.  Evaluation of behavioral changes and subjective distress after exposure to coercive inpatient interventions.

Authors:  Irina Georgieva; Cornelis L Mulder; Richard Whittington
Journal:  BMC Psychiatry       Date:  2012-05-30       Impact factor: 3.630

7.  Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.

Authors:  Heidi J Wehring; Sheryl Thedford; Maju Koola; Deanna L Kelly
Journal:  J Cent Nerv Syst Dis       Date:  2011-06-01

8.  Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study.

Authors:  Jayati Das-Munshi; Dinesh Bhugra; Mike J Crawford
Journal:  BMC Med       Date:  2018-04-18       Impact factor: 8.775

9.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

10.  Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication.

Authors:  Til Wykes; Diana Rose; Paul Williams; Anthony S David
Journal:  BMC Psychiatry       Date:  2013-01-15       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.